The results of a Phase 1 trial suggest that the experimental drug PD 0332991 may be a safe and effective treatment for pre-treated multiple myeloma patients.

Dr. Ruben Niesvizky of the Weill Cornell Medical College, who presented the results at the American Society of Hematology (ASH) annual meeting in Orlando last month, pointed out that data about efficacy is limited at this point because it was a Phase 1 trial. However, he added “We are encouraged [by the results] because we have seen two very good partial responses.”

PD 0332991, which is …